A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

• Confirmed diagnosis of chronic lymphocytic leukemia (CLL)/ small lymphocyticlymphoma (SLL) and active disease clearly documented to have a need to initiatetherapy

• Has previously untreated CLL/SLL participants without tumor protein 53 (TP53)aberrations and documented 11q status and immunoglobulin heavy chain gene (IGHV)mutational status

• The ability to swallow and retain oral medication

Exclusion Criteria:

• Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection

• Gastrointestinal dysfunction that may affect drug absorption (eg, gastric bypasssurgery, gastrectomy)

• Known additional malignancy that is progressing or has required active treatmentwithin the past 3 years, except basal cell carcinoma of skin, squamous cellcarcinoma of skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer insitu) that have undergone potential curative therapy

• History of severe bleeding disorders

• Not adequately recovered from major surgery or has ongoing surgical complications